BBOT vs BIIB · rev $7.5M vs P/E 21, rev $9.89B
BridgeBio Oncology Therapeutics, Inc. (BBOT) versus Biogen Inc (BIIB) — a side-by-side from cached financials, not a winner call.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Latest reported BBOT revenue for 2026-06-30 was $7.5M. Net income was -$98.6M. Revenue was up 90.0% from 2026-03-31 to 2026-06-30. BBOT currently screens at market cap $610.4M.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
BBOT currently screens at market cap $610.4M. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Not investment advice. Open the BBOT and BIIB stock pages for the full models.
Not investment advice.